This company has been marked as potentially delisted and may not be actively trading. OvaScience (OVAS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OVAS vs. ZYME, CALT, MBX, ETHZ, SBTX, AVTE, BIOA, NLTX, CYBN, and VIRIShould you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), MBX Biosciences (MBX), Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), Cybin (CYBN), and Virios Therapeutics (VIRI). OvaScience vs. Its Competitors Zymeworks Calliditas Therapeutics AB (publ) MBX Biosciences Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics BioAge Labs Neoleukin Therapeutics Cybin Virios Therapeutics Zymeworks (NASDAQ:ZYME) and OvaScience (NASDAQ:OVAS) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment. Do insiders & institutionals hold more shares of ZYME or OVAS? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 22.5% of OvaScience shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 7.4% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, ZYME or OVAS? Zymeworks has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Does the media favor ZYME or OVAS? In the previous week, Zymeworks' average media sentiment score of 0.00 equaled OvaScience'saverage media sentiment score. Company Overall Sentiment Zymeworks Neutral OvaScience Neutral Is ZYME or OVAS more profitable? Zymeworks has a net margin of -59.96% compared to OvaScience's net margin of -10,128.37%. Zymeworks' return on equity of -21.59% beat OvaScience's return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-59.96% -21.59% -16.52% OvaScience -10,128.37%-47.06%-42.39% Do analysts prefer ZYME or OVAS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00OvaScience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, ZYME or OVAS? OvaScience has lower revenue, but higher earnings than Zymeworks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$122.87M10.09-$122.69M-$0.97-17.01OvaScience$290K1,339.30-$50.97MN/AN/A SummaryZymeworks beats OvaScience on 6 of the 10 factors compared between the two stocks. Get OvaScience News Delivered to You Automatically Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVAS vs. The Competition Export to ExcelMetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$388.40M$1.05B$6.10B$10.53BDividend YieldN/A4.84%5.51%4.67%P/E RatioN/A1.2885.6826.86Price / Sales1,339.3030.43583.23185.42Price / CashN/A17.6426.3031.10Price / Book6.027.6513.256.72Net Income-$50.97M-$7.66M$3.30B$276.44M OvaScience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVASOvaScienceN/A$10.84+4.2%N/A+632.4%$388.40M$290K0.00N/AZYMEZymeworks0.0128 of 5 stars$16.90-0.2%N/AN/A$1.27B$76.30M-17.42460CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180MBXMBX BiosciencesN/A$16.75-6.4%$39.88+138.1%N/A$562.70MN/A-3.6936ETHZFlag Ship AcquisitionN/A$2.58+8.4%N/AN/A$424.23MN/A-0.177SBTXSilverback TherapeuticsN/A$10.09+0.4%N/A-27.3%$363.83MN/A-4.1783High Trading VolumeAVTEAerovate TherapeuticsN/A$9.11+5.6%N/A-87.7%$264.05MN/A-3.0520High Trading VolumeBIOABioAge Labs0.2752 of 5 stars$5.90-0.3%N/AN/A$211.52MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$17.98+3.7%N/A-54.0%$168.93MN/A-5.7890High Trading VolumeCYBNCybinN/A$6.21+3.8%$85.00+1,268.8%N/A$156.42MN/A-1.4250High Trading VolumeVIRIVirios TherapeuticsN/A$7.07-8.2%$5.00-29.3%+3,688.4%$136.15MN/A-26.195Gap Down Related Companies and Tools Related Companies ZYME Competitors CALT Competitors MBX Competitors ETHZ Competitors SBTX Competitors AVTE Competitors BIOA Competitors NLTX Competitors CYBN Competitors VIRI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVAS) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
